Edesa Biotech is trading 7.1% up at $5.32 in after-hours trading, appearing to stage a technical rebound from its previous session decline.

  • The stock is recovering from a 7.1% drop to $4.97 at the July 28 close, which also occurred without a clear fundamental catalyst.
  • No fresh company-specific headlines, FDA decisions, or earnings releases have been issued this evening to explain the price action.
  • The move likely represents a low-liquidity technical reaction rather than a news-driven rerating of the company.